Lung Cancer News & Features
There have been many recent changes in lung cancer, including updated early detection possibilities and changes in diagnostic procedures, reporting, and treatment options. These are reviewed in a presentation at the 2018 ONA Navigation Summit.
A review of current options and ongoing trials for managing ARIE, a common esophageal adverse effect caused by radiotherapy to the thoracic region for lung, breast, or head and neck cancers, or lymphoma.
Study results presented at 2018 ASCO Annual Meeting demonstrated effectiveness of ado-trastuzumab emtansine in non-breast non-gastric HER2-amplified cancers.
Response to Rapamycin Analogs but not PD-1 Inhibitors in PTEN-mutated Metastatic Non-small Cell Lung Cancer With High Tumor Mutational Burden
[Lung Cancer: Targets and Therapy] This case study demonstrates that genomic profiling may still benefit patients who fail checkpoint inhibitor therapy despite having high tumor mutational burden and PD-L1 positivity.
Researchers observed a decrease in the age-specific incidence of lung cancer among both men and women aged 30 to 54 years over the past two decades; the declines among men were steeper.
Multiple Treatment Modalities for Brain Metastasis in Patients With EGFR-mutant Non-small Cell Lung Cancer
[OncoTargets and Therapy] Management of brain metastases in patients with EGFR-mutant NSCLC is controversial. In this study, researchers find combination and sequential treatment with EGFR-TKIs, chemotherapy, and radiotherapy is beneficial.
A study presented at the 2018 ONS Annual Congress explored the feasibility of an advanced practice nurse-led lung cancer screening program at ambulatory outpatient clinics.
[Lung Cancer: Targets and Therapy] Italian researchers report on the role of GLI1 in the development of lung cancer, and review its potential as an effective therapy for lung cancer.
The integrated proteomic classifier performed better than positron emission tomography, validated lung nodule risk models, and physician cancer probability estimates.
A review of the literature on follow-up after positive screening results led researchers to a consensus opinion on timing of diagnostic tests for 4 cancers: breast, cervical, colorectal, and lung.
Lung Cancer Clinical Trials
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
- Drug Classification of Trastuzumab
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|